Jefferies has upgraded its price target on DaVita DVA from $95 to $101 in a research report published today.
In the report, Jefferies states, "Our $101 PT is based on a 5-year DCF analysis that assumes a WACC of 7.3% and a terminal EBITDA-MI multiple of 8.5x (in-line with historical trading range). While our estimates do not include DSI contribution, our valuation model does. Risks: Uncertainties stemming from the transition to Medicare's bundled payment system and potential commercial payor pricing pressure."
In spite of raising its price target, Jefferies still has a Hold rating on DaVita's shares.
In yesterday's trading, DaVita's shares were up by 1.23% to close the day at $89.17.
Market News and Data brought to you by Benzinga APIs© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Loading...
date | ticker | name | Price Target | Upside/Downside | Recommendation | Firm |
---|
Benzinga simplifies the market for smarter investing
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Join Now: Free!
Already a member?Sign in